The mechanisms of these agents offer promising avenues for breast cancer treatment, and suggest that circulating adiponectin levels and AdipoR expression may serve as potential biomarkers for identifying patient populations likely to benefit from such therapies. The gene discussed is ADIPOQ; the disease is breast cancer.